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Abstract Background: BRAF/MEK inhibitor combinations are established treatments for
BRAF V600emutant melanoma based on demonstrated benefits on progression-free survival
(PFS) and overal l survival (OS). Here, we report an updated analysis of the
COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib]
in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up.
Methods: In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF
V600emutant melanoma, untreated or progressed after first-line immunotherapy, were rando-
mised 1:1:1 to 450 mg of encorafenib QD þ 45 mg of binimetinib BID (COMBO450) vs
960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib ENCO QD (ENCO300). An
updated analysis was conducted that included PFS, OS, objective response rate, safety and
tolerability and analyses of results by prognostic subgroups.
Results: At data cutoff, there were 116, 113 and 138 deaths in the COMBO450, ENCO300 and
VEM treatment arms, respectively. The median OS was 33.6 months (95% confidence interval
[CI], 24.4e39.2) for COMBO450, 23.5 months (95% CI, 19.6e33.6) for ENCO300 and 16.9
months (95% CI, 14.0e24.5) for VEM. Compared with VEM, COMBO450 decreased the risk
of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48e0.79). The updated median PFS for
COMBO450 was 14.9 months (95% CI, 11.0e20.2), ENCO300 was 9.6 months (95% CI, 7.4
e14.8) and VEM was 7.3 months (95% CI, 5.6e7.9). PFS was longer for COMBO450 vs VEM
(HR, 0.51; 95% CI, 0.39e0.67). Landmark OS and PFS results show consistent results for
each year analysed. Subgroups all favoured COMBO450 vs VEM.
Conclusions: Updated PFS and OS results for COMBO450 from the COLUMBUS trial
demonstrate a long-term benefit in patients with advanced BRAF V600emutated melanoma.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Based on improved overall survival (OS) and the toler-
ability profile relative to BRAF inhibitor monotherapy,
combination BRAF/MEK inhibitor therapy is now the
standard of care in BRAF V600Eemutant locally
advanced or metastatic melanoma [1e3]. Encorafenib is
a highly selective ATP-competitive BRAF inhibitor
developed with unique pharmacological properties
aimed at improving efficacy and tolerability over other
approved BRAF inhibitors [4]. Preclinical studies have
demonstrated increased potency against BRAF V600
mutations [5e7] and extended duration of target inhi-
bition and shorter serum half-life that may delay resis-
tance and translate to improved tolerability [4e6].
Binimetinib is a potent, selective allosteric, ATP-
uncompetitive MEK1/2 inhibitor that has a shorter
half-life than other MEK1/2 inhibitors, which may
provide more rapid resolution of toxicity upon dose
interruption [8].
The phase 3 COLUMBUS study compared 450 mg of
encorafenib once daily (QD) þ 45 mg of
binimetinib twice daily (BID, COMBO450) vs 300 mg of
encorafenib QD (ENCO300) or 960 mg of
vemurafenib BID (VEM) in patients with BRAF V600E/
Kemutant melanoma [9,10]. Compared with VEM,
COMBO450 extended median progression-free survival
(PFS) (7.3 vs 14.9 months; hazard ratio [HR], 0.54; 95%
confidence interval [CI], 0$41e0$71) and median overall
survival (16.9 vs 33.6 months; HR, 0.61; 95% CI,
0$47e0$79). Mature landmark analyses on PFS and OS,
as well as analyses of some prognostic subgroups,
require long-term follow-up.
Here, we report an updated analysis of the CO-
LUMBUS trial in patients with BRAF V600 mutant
locally advanced unresectable or metastatic melanoma
in an updated landmark analysis.
2. Methods
2.1. Trial design
The design and primary analyses have been published
[9,10]; NCT01909453). Briefly, COLUMBUS was a two-
part, multicenter, randomised, open-label, phase 3 study
with patients enrolled from 162 hospitals in 28 coun-
tries. Enrolment for part 1 occurred between December
30, 2013, and April 10, 2015. In part 1 of COLUMBUS,
577 patients with advanced/metastatic BRAF
V600emutant melanoma, untreated or progressed after
first-line immunotherapy, were randomised 1:1:1 to
COMBO450 vs VEM or ENCO300.
2.2. Patient eligibility
Key eligibility criteria included that patients had to be at
least 18 years of age with a histologically confirmed
diagnosis of locally advanced, unresectable or metastatic
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cutaneous melanoma or unknown primary melanoma
classified as American Joint Committee on Cancer
(AJCC) stage IIIB, IIIC or IV; be treatment naive or
had progressed on or after previous first-line immuno-
therapy; BRAF V600E or BRAF V600K mutation or
both in tumour tissue as ascertained by central genetic
mutation analysis with the bioMerieux THxID BRAF
diagnostic test before enrolment; have Eastern Cooper-
ative Oncology Group (ECOG) performance status of
0 or 1; and/or have adequate bone marrow, organ
function and laboratory parameters and at least one
measurable lesion in accordance with guidelines based
on Response Evaluation Criteria in Solid Tumors. Pa-
tients were ineligible if they had untreated central ner-
vous system lesions; uveal or mucosal melanoma; a
history of leptomeningeal metastases; Gilbert syndrome;
history, current evidence or risk of retinal vein occlu-
sion; previous BRAF inhibitor or MEK inhibitor
treatment; previous use of systemic chemotherapy,
extensive radiotherapy or an investigational agent other
than previous immunotherapy for locally advanced,
unresectable or metastatic melanoma.
2.3. End-points and assessments
An updated analysis including PFS, OS, objective
response rate (ORR), safety and tolerability and ana-
lyses of results by prognostic subgroups including
elevated lactate dehydrogenase (LDH) and degree of
organ involvement were conducted after an additional
12 months’ follow-up after the initial OS analysis.
Additional details on methodology can be found in
previous publications [9,10]. Safety was analysed in pa-
tients who received at least one dose of study drug and
one postbaseline safety assessment and summarised
descriptively. Select adverse events of interest for
BRAF/MEK inhibitors were summarised by when they
occurred (i.e. in the first 6 months, 6e12 months, 12e18
months and 18e24 months) for patients on treatment
for at least 24 months. The incidence of select adverse
events associated with BRAF/MEK inhibitors (left
ventricular dysfunction, rash, skin papilloma, serous
retinopathy, pyrexia and transaminases increased) were
summarised by month for all patients over the first 24
months of the study.
2.4. Statistical analyses
An updated analysis was conducted after an additional
12 months’ follow-up relative to initial OS analysis with
a cut-off date of November 2018. Efficacy end-points
were assessed in the intent-to-treat population (defined
as all randomly assigned patients). The median dura-
tions of the follow-up for OS and PFS were estimated by
reverse Kaplan-Meier analysis. The Kaplan-Meier
method was used to estimate rates of OS and PFS; the
log-rank test, stratified by AJCC stage IIIB, IIIC,
IVM1a and IVM1b vs IVM1c and ECOG performance
status (0 vs 1), was used to compare distributions.
Subgroup analyses of baseline variables and potential
prognostic factors, including previous immunotherapy,
were also specified. HRs were estimated by the use of
Cox proportional hazard regression models. Additional
information on the statistical analyses have been previ-
ously published [9,10]).
3. Results
3.1. Participants
Baseline patient and disease characteristics are sum-
marised in Table 1. A total of 577 patients were rand-
omised in part 1 of the COLUMBUS study (COMB450:
192; ENCO300: 194 and VEM: 191). Characteristics
were similar among the treatment groups and consistent
with mutant locally advanced unresectable or metastatic
melanoma. Of the 577 patients at baseline, 154 patients
(27%) had an elevated LDH level. The disposition of
patients in the study is summarised in Table 2. At the
time of data cutoff for this analysis (November 2018), 36
patients (19%) were continuing to receive COMBO450,
20 patients (10%) were continuing to receive
ENCO300 and 9 patients (5%) were continuing to
receive VEM. Discontinuations due to adverse events
occurred in 10% of patients in the COMBO450 group,
12% in the ENCO300 group and 14% in the VEM
group.
Table 1
Baseline patient and disease characteristics.
Characteristic COMBO450
n Z 192
ENCO300
n Z 194
VEM
n Z 191
Median age (range),
years
57 (20e89) 54 (23e88) 56 (21e82)
Male, n (%) 115 (59.9) 108 (55.7) 111 (58.1)
ECOG performance
status 0
136 (70.8) 140 (72.2) 140 (73.3)
LDH > ULN 55 (29) 47 (24) 52 (27%)
LDH  ULN 137 (71%) 147 (76%) 139 (73%)
BRAF mutation status
BRAFV600E 170 (89%) 173 (89%)a 168 (88%)
BRAFV600K 22 (11%) 19 (10%)a 23 (12%)
Tumour stage at study entry, n (%)
IIIB/IIIC 9 (4.7) 6 (3.1) 11 (5.7)
IVM1a 26 (13.5) 29 (14.9) 24 (12.6)
IVM1b 34 (17.7) 39 (20.1) 31 (16.2)
IVM1c 123 (64.1) 120 (61.9) 125 (64.4)
Number of organs involved
1 47 (24.5) 56 (28.9) 45 (23.6)
2 58 (30.2) 52 (26.8) 59 (30.9)
3 87 (45.3) 86 (44.3) 87 (45.6)
COMBO450 Z encorafenib 450 mg QD þ binimetinib 45 mg BID;
ECOG Z Eastern Cooperative Oncology Group;
ENCO300Z encorafenib 300 mg QD; LDHZ lactate dehydrogenase;
ULN Z upper limit of normal; VEM Z vemurafenib 960 mg BID.
a Two observations were indeterminate.
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3.2. Efficacy outcomes
Across arms, the median follow-up for OS was 48.8
months. The median OS for COMBO450 was 33.6
months (95% CI, 24.4e39.2), for ENCO300 was 23.5
months (95% CI, 19.6e33.6) and for VEM was 16.9
months (95% CI, 14.0e24.5; Fig. 1a). Compared with
VEM, COMBO450 decreased the risk of death by 39%
(HR, 0.61; 95% CI, 0.48e0.79]). A landmark analysis
showed a higher rate of OS for COMBO450 at year 1,
2 and 3 (Fig. 1b). At 3 years, the OS rates were 47% for
COMBO450, 41% for ENCO300 and 31% for VEM. In
general, subgroup analyses for the comparison of
COMBO450 with VEM showed point estimates in
favour of COMBO450 across various populations
(Fig. 2). OS results for the subgroups for LDH high,
LDH normal and LDH normal and <3 affected organ
sites are shown in Fig. 3. In the LDH normal subgroup,
the median OS for COMBO450 was not reached,
whereas the median OS for VEM was 24.5 months.
Similarly, for patients with LDH normal and <3 organ
sites, the median OS for COMBO450 was not reached,
whereas the median OS for VEM was 28.1 months. The
median OS for the high LDH subgroup was 11.4 months
for COMBO450 and 9.6 months for VEM (HR,0.93;
[95% CI, 0.62, 1.39]).
A summary of patients receiving antineoplastic
therapy after study drug discontinuation by line of
therapy for each treatment arm is shown in Table 3.
After study drug discontinuation, systemic treatments
were received by 82 (53%) of 156 patients in the
COMBO450 group, 107 (62%) of 172 in the ENCO300
group and 122 (69%) of 177 in the VEM group (Table
3). Anti-cytotoxic T-lymphocyteeassociated protein 4
(CTLA-4) and antieprogrammed death 1 or anti-
eprogrammed death ligand 1 immunotherapies were the
most frequent first and second subsequent regimens and
were received by approximately the same proportion of
patients in all groups. Approximately half of the pa-
tients who received immunotherapy as the first post-
study therapy were treated with antieCTLA-4 mono-
therapy (i.e. ipilimumab) across all study arms (Table 3).
At the time of data cutoff, disease progression or
death had occurred in 350 of 577 patients (61%). The
updated median PFS by central review was 14.9 months
(95% CI, 11.0e20.2) for COMBO450, 9.6 months (95%
CI, 7.4e14.8) for ENCO300 and 7.3 months (95% CI,
5.6e7.9) for VEM. The PFS was longer for COMBO450
vs VEM (HR, 0.51; 95% CI, 0.39e0.67). A landmark
analysis showed a higher rate of PFS for COMBO450 at
year 1, 2 and 3 (Fig. 4). At 3 years, the PFS rates were
29% for COMBO450, 25% for ENCO300 and 14% for
VEM.
ORR results were higher for COMBO450 than for
VEM (Table 4). Confirmed overall response by masked
independent central review was observed in 64% (95%
CI, 56e70) of 192 patients in the COMBO450 group,
52% (95% CI, 44e59) of 194 patients in the ENCO300
group and 41% (95% CI, 34e48) of 191 patients in the
VEM group (Table 4). By local review, a confirmed
overall response was observed in 76% (95% CI, 69e81)
patients in the COMBO450 group, in 58% (95% CI,
51e65) in the ENCO300 group and in 49% (95% CI,
42e57) in the VEM group. The median duration of
response was analysed by central and local reviews. By
central review, it was 18.6 months (95% CI, 12.7e24.1)
in the COMBO450 group, 15.5 months (95% CI,
11.1e28.6) in the ENCO300 group and 12.3 months
(95% CI, 6.9e14.5) in the VEM group. Duration of
response assessed by local investigator was similar.
3.3. Safety
A total of 68%, 68% and 66% of patients experienced
grade 3/4 adverse events in the COMBO450,
ENCO300 and VEM groups, respectively (Table 5).
Adverse event associated with BRAF inhibitors and
MEK inhibitors did not increase substantially in time
since the updated analysis (Fig. 5). Adverse events led to
discontinuation in 16%, 15% and 17% and dose reduc-
tion/interruption in 55%, 71% and 62% for COMBO450,
ENCO300 and VEM, respectively. On-treatment deaths
occurred in 13%, 8% and 11% of patients for
COMBO450, ENCO300 and VEM, respectively.
Select adverse events of interest for BRAF/MEK in-
hibitors occurring in the first 6 months, 6e12 months,
12e18 months and 18e24 months of treatment with
COMBO450 are shown in Table 6 (only patients who
received treatment for at least 24 months were included
in the analysis [n Z 59]). Across the adverse events
evaluated, patients had less burden of toxicity later in
the 2-year analysis. Fig. 6 shows the incidence of adverse
events for select adverse events associated with BRAF/
MEK inhibitors (left ventricular dysfunction, rash, skin
Table 2
Patient disposition.
Variable COMBO450
n Z 192
n (%)
ENCO300
n Z 194
n (%)
VEM
n Z 191
n (%)
Untreated 0 2 (1.0) 5 (2.6)
Discontinued treatment 156 (81.3) 172 (88.7) 177 (92.7)
Progressive disease 104 (54.2) 101 (52.1) 111 (58.1)
Adverse event 20 (10.4) 24 (12.4) 26 (13.6)
Physician or patient
decisiona
21 (11.0) 35 (23.2) 35 (18.3)
Death 9 (4.7) 1 (0.5) 4 (2.1)
Otherb 2 (1.0) 1 (0.5) 1 (0.5)
Treatment ongoingc 36 (18.8) 20 (10.3) 9 (4.7)
COMBO450 Z encorafenib 450 mg QD þ binimetinib 45 mg BID;
ENCO300 Z encorafenib 300 mg QD; VEM Z vemurafenib 960 mg
BID.
a Physician or patient/guardian decision.
b Includes protocol violation, lost to follow-up and new therapy for
study indication.
c As of the data cut-off date of November 19, 2018.
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papilloma, serous retinopathy, pyrexia and trans-
aminases increased) by month for all patients over the
first 24 months of the study. The incidence of some of
these adverse events generally appears to be less
frequent over time.
4. Discussion
These landmark analyses of the phase 3, randomised
COLUMBUS trial in patients with BRAF-mutant mel-
anoma treated with encorafenib plus binimetinib show
improved OS and PFS for COMBO450 vs VEM in a
follow-up analysis. The current updated analyses
confirmed previous findings of prolonged OS for
COMBO450 vs VEM: 33.6 vs 16.9 months and PFS:
14.9 vs 7.3 months, with similar results across a broad
range of subgroups, although patients with elevated
LDH seem to have limited benefit. Safety results were
consistent with the known tolerability profile of
COMBO450, with nausea, diarrhoea, and vomiting as
the most common adverse events. No new safety con-
cerns were noted in this update, and patients maintain-
ing response have less burden of toxicity in the later
years. These results for COMBO450 from the CO-
LUMBUS trial demonstrate the potential for a long-
term benefit in patients with advanced BRAF
V600emutated melanoma.
The updated analysis presented in this manuscript is
consistent with previous reports of the COLUMBUS
study [9,10]), with a durable benefit in patients with
BRAF-mutant metastatic melanoma. Based on sub-
group analysis and multivariable regression modelling
Fig. 1. Overall survival (a) and landmark analysis (b): COMBO450 vs VEM. COMBO450Z encorafenib 450 mg QD þ binimetinib 45 mg
BID; VEM Z vemurafenib 960 mg BID.
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to account for prespecified baseline covariates,
COMBO450 showed consistent improvement relative to
VEM across a broad range of patients. As expected,
patients with normal LDH performed better than pa-
tients with high LDH in all treatment groups, as seen in
previous trials involving other BRAF/MEK inhibitors
[2,11e13]. Results in the high LDH subgroup favoured
COMBO450 relative to VEM (median OS for
COMBO450 Z 11.4 months; VEM Z 9.6 months).
Additional research is needed to understand how treat-
ment for this group of patients can be optimised. As
noted previously, the types of systemic treatment
received after study drug discontinuation were generally
similar in all three groups, with slightly higher use of
Fig. 2. Overall survival subgroups: COMBO450 vs VEM. COMBO450 Z encorafenib 450 mg QD þ binimetinib 45 mg BID;
VEM Z vemurafenib 960 mg BID.
Fig. 3. Overall survival subgroups: (a). LDH high; (b). LDH normal; and (c). LDH normal and <3 metastatic organ sites. LDHZ lactate
dehydrogenase.
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BRAF/MEK inhibitor regimens in the encorafenib and
vemurafenib groups, as expected in patients who prog-
ress on monotherapy [10]. Of the 33% patients in the
trial who received immunotherapy as the first post-study
therapy, approximately half were treated with anti-
eCTLA-4 monotherapy (i.e. ipilimumab) across all
study arms. Subsequent therapy does not appear to
account for observed differences in overall survival
observed in the COLUMBUS group.
The safety profile of COMBO450 in the updated
analysis is also consistent with previous observations.
The incidence of pyrexia and photosensitivity with
encorafenib plus binimetinib appear to be lower than
shown in previous trials of established BRAF/MEK
inhibitor combinations [2,3,13]. As noted with temporal
analysis of select adverse events over the course of the
study, patients appeared to have less burden of toxicity
later in the 2-year analysis (i.e. as the study progressed).
This observation is similar to what has been observed in
a previous BRAF/MEK inhibitor study analysis [14].
In this analysis, the PFS curve for encorafenib plus
binimetinib appears to begin to level out in the later
years, suggesting a potential stabilisation of patients’
disease (i.e. the PFS rates for COMBO450 were 37% and
29% for years 2 and 3, respectively). A similar obser-
vation was noted by Robert et al. in a pooled analysis of
the phase 3 dabrafenib-trametinib melanoma trials, in
which they observed PFS rates of 31%, 24%, 21% and
19% for years 2 through 5 [11]. No direct comparisons of
encorafenib plus binimetinib with other BRAF/MEK
inhibitor combinations are available. Although the
COLUMBUS trial was not designed to compare
encorafenib plus binimetinib with other BRAF/MEK
inhibitor regimens, the results compare favourably to
prior studies with other agents. For example, the median
PFS in phase 3 trials evaluating dabrafenib-trametinib
(COMBI-d and COMBI-v trials [2,3,11]) and
vemurafenib-cobimetinib (coBRIM [13]) ranged from
11.0 to 12.3 months. In this update, the median PFS for
encorafenib plus binimetinib was 14$9 months (95% CI,
11.0e20.2). In preclinical studies, encorafenib,
dabrafenib and vemurafenib all inhibit BRAF V600E
kinase activity at similar concentrations. However,
encorafenib has a longer dissociation half-life than for
dabrafenib or vemurafenib (>30 h vs 2 h vs 0e5 h,
respectively), resulting in longer inhibition of pERK [6].
Increased antitumour activity in BRAF V600emutant
cell lines was also observed for encorafenib in preclinical
studies [4,6]. These observations appear to support the
hypothesis that extended pathway inhibition can lead to
improved clinical outcomes.
There are several limitations of this analysis that
should be noted. First, OS was not the primary end-
point of the study; however, OS was a key efficacy end-
point and the comparison of the COMBO450 group
with the VEM group was included in the testing hier-
archy in COLUMBUS. These data will continue to be
monitored and additional updates will be published as
more data become available. Finally, the COLUMBUS
study did not enrol patients with metastatic brain
metastasis, and therefore data on this subgroup are not
available in this updated analysis. A recent retrospective
analysis showed combination therapy with encorafenib
plus binimetinib elicited intracranial activity in patients
with BRAF-mutant melanoma brain metastases,
including in patients previously treated with BRAF/
MEK inhibitors [15]. This population is currently being
prospectively evaluated in a phase 2 trial to further
evaluate efficacy and safety of two dosing regimens of
encorafenib plus binimetinib in patients with BRAF
V600emutant melanoma brain
metastases (NCT03911869).
Table 3
Systemic treatment after study drug discontinuation.
Variable COMBO450
N Z 156 n
(%)
ENCO300
N Z 172
n (%)
VEM
N Z 177
n (%)
Any regimen 82 (52.6) 107 (62.2) 122 (68.9)
First line after COLUMBUS study
treatment
82 (52.6) 107 (62.2) 122 (68.9)
At least one immunotherapy 59 (37.8) 54 (31.4) 60 (33.9)
AntieCTLA-4 29 (18.6) 25 (14.5) 29 (16.4)
AntieCTLA-4 þAnti-PD1 4 (2.6) 0 1 (0.6)
Anti-PD1 25 (16.0) 28 (16.3) 28 (15.8)
Other 1 (0.6) 1 (0.6) 2 (1.1)
At least one targeted therapy 16 (10.3) 37 (21.5) 49 (27.7)
BRAFi 9 (5.8) 13 (7.6) 12 (6.8)
BRAFi þ MEKi 5 (3.2) 23 (13.4) 29 (16.4)
Other 2 (1.3) 1 (0.6) 8 (4.5)
At least one chemotherapy 8 (5.1) 17 (9.9) 15 (8.5)
Second line after COLUMBUS
study treatment
30 ( 19.2) 34 ( 19.8) 56 ( 31.6)
At least one immunotherapy 17 (10.9) 23 (13.4) 32 (18.1)
AntieCTLA-4 4 (2.6) 7 (4.1) 5 (2.8)
AntieCTLA-4 þAnti-PD1 1 (0.6) 3 (1.7) 2 (1.1)
Anti-PD1 11 (7.1) 12 (7.0) 22 (12.4)
Other 1 (0.6) 1 (0.6) 3 (1.7)
At least one targeted therapy 8 (5.1) 4 (2.3) 19 (10.7)
BRAFi 1 (0.6) 0 7 (4.0)
BRAFi þ MEKi 5 (3.2) 3 (1.7) 8 (4.5)
Other 2 (1.3) 1 (0.6) 4 (2.3)
At least one chemotherapy 6 (3.8) 7 (4.1) 7 (4.0)
Third line or later after
COLUMBUS study treatment
13 (8.3) 12 (7.0) 18 (10.2)
At least one immunotherapy 10 (6.4) 5 (2.9) 8 (4.5)
AntieCTLA-4 0 0 3 (1.7)
AntieCTLA-4 þAnti-PD1 2 (1.3) 2 (1.2) 1 (0.6)
Anti-PD1 8 (5.1) 2 (1.2) 4 (2.3)
Other 1 (0.6) 1 (0.6) 0
At least one targeted therapy 3 (1.9) 7 (4.1) 12 (6.8)
BRAFi 1 (0.6) 1 (0.6) 2 (1.1)
BRAFi þ MEKi 2 (1.3) 5 (2.9) 9 (5.1)
Other 1 (0.6) 1 (0.6) 2 (1.1)
At least one chemotherapy 3 (1.9) 4 (2.3) 5 (2.8)
COMBO450 Z encorafenib 450 mg QD þ binimetinib 45 mg BID;
ENCO300 Z encorafenib 300 mg QD; VEM Z vemurafenib 960 mg
BID; anti-PD1 Z antieprogrammed death 1; antieCTLA-4 Z anti-
cytotoxic T-lymphocyteeassociated protein 4; COLUMBUS.
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In conclusion, patients treated with encorafenib plus
binimetinib had longer PFS and OS than those treated
with vemurafenib, with landmark analyses showing
consistent improved OS and PFS for COMBO450 vs
VEM for each year. Safety results were consistent with
the known tolerability profile of COMBO450, and the
toxicity burden was reduced over time. These data
reinforce encorafenib plus binimetinib as an important
treatment option for patients with BRAF-mutant mel-
anoma. Trials are planned and underway to further
assess the use of encorafenib and binimetinib in various
patient populations, including as earlier line treatment
and in high-risk patients.
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Table 4
Confirmed response rates.
Variable COMBO450
N Z 192 n (%)
ENCO300
N Z 194 n (%)
VEM
N Z 191 n (%)
Central review Local review Central review Local review Central review Local review
Best overall response
Complete response 24 (12.5) 40 (20.8) 14 (7.2) 20 (10.3) 16 (8.4) 16 (8.4)
Partial response 98 (51.0) 105 (54.7) 86 (44.3) 93 (47.9) 62 (32.5) 78 (40.8)
Stable disease 55 (28.6) 33 (17.2) 63 (32.5) 55 (28.3) 77 (40.3) 66 (34.5)
Progressive diseasea 15 (7.8) 14 (7.3) 31 (16.0) 26 (13.4) 36 (18.8) 31 (16.3)
Overall responseb 122 (63.5) 145 (75.5) 100 (51.5) 113 (58.2) 78 (40.8) 94 (49.2)
95% CI (56.3, 70.4) (68.8, 81.4) (44.3, 58.8) (51.0, 65.3) (33.8, 48.2) (41.9, 56.5)
Disease controlc 177 (92.2) 178 (92.7) 163 (84.0) 168 (86.6) 155 (81.2) 160 (83.8)
95% CI (87.4, 95.6) (88.1, 96.0) (78.1, 88.9) (81.0, 91.1) (74.9, 86.4) (77.8, 88.7)
Data are n (%) or n (%; 95% CI) in the efficacy population. *Includes patients with non-measurable disease and a status of non-complete response
or non-progressive disease. CIZ confidence interval; COMBO450Z encorafenib 450 mg QD þ binimetinib 45 mg BID; ENCO300Z encorafenib
300 mg QD; VEM Z vemurafenib 960 mg BID.
a Includes patients with best response of unknown or no assessment.
b Overall response was defined as complete response plus partial response.
c Disease control defined as the proportion of patients with a best overall response of complete response, partial response, stable disease, or
non-complete response or non-progressive disease.
Table 5
Adverse events occurring in 20% of patients.
Preferred term
COMBO450
N Z 192
ENCO300
N Z 192
VEM
N Z 186
All grades n
(%)
Grade III/IV n
(%)
All grades n
(%)
Grade III/IV n
(%)
All grades n
(%)
Grade III/IV n
(%)
Total 189 (98.4) 131 (68.2) 191 (99.5) 130 (67.7) 186 (100) 122 (65.6)
Nausea 84 (43.8) 4 (2.1) 74 (38.5) 8 (4.2) 65 (34.9) 3 (1.6)
Diarrhea 74 (38.5) 5 (2.6) 29 (15.1) 4 (2.1) 64 (34.4) 4 (2.2)
Vomiting 61 (31.8) 4 (2.1) 56 (29.2) 9 (4.7) 30 (16.1) 2 (1.1)
Fatigue 57 (29.7) 4 (2.1) 50 (26.0) 1 (0.5) 57 (30.6) 4 (2.2)
Arthralgia 55 (28.6) 2 (1.0) 87 (45.3) 18 (9.4) 86 (46.2) 11 (5.9)
Blood creatine phosphokinase increased 50 (26.0) 15 (7.8) 2 (1.0) 0 4 (2.2) 0
Headache 49 (25.5) 4 (2.1) 55 (28.6) 6 (3.1) 37 (19.9) 2 (1.1)
Constipation 48 (25.0) 0 31 (16.1) 0 13 (7.0) 1 (0.5)
Asthenia 42 (21.9) 3 (1.6) 42 (21.9) 5 (2.6) 35 (18.8) 8 (4.3)
Pyrexia 38 (19.8) 7 (3.6) 32 (16.7) 2 (1.0) 53 (28.5) 0
Dry skin 31 (16.1) 0 58 (30.2) 1 (0.5) 43 (23.1) 0
Myalgia 31 (16.1) 0 55 (28.6) 19 (9.9) 34 (18.3) 1 (0.5)
Rash 31 (16.1) 3 (1.6) 40 (20.8) 4 (2.1) 56 (30.1) 6 (3.2)
Hyperkeratosis 29 (15.1) 1 (0.5) 77 (40.1) 7 (3.6) 54 (29.0) 0
Alopecia 28 (14.6) 0 108 (56.3) 0 70 (37.6) 0
Pruritus 24 (12.5) 1 (0.5) 42 (21.9) 1 (0.5) 20 (10.8) 0
Pain in extremity 23 (12.0) 2 (1.0) 43 (22.4) 2 (1.0) 27 (14.5) 2 (1.1)
Decreased appetite 19 (9.9) 0 40 (20.8) 1 (0.5) 36 (19.4) 2 (1.1)
Palmoplantar keratoderma 19 (9.9) 0 51 (26.6) 4 (2.1) 33 (17.7) 2 (1.1)
Palmar-plantar erythrodysaesthesia
syndrome
14 (7.3) 0 99 (51.6) 26 (13.5) 26 (14.0) 2 (1.1)
Keratosis pilaris 9 (4.7) 0 33 (17.2) 0 43 (23.1) 0
Photosensitivity 7 (3.6) 1 (0.5) 7 (3.6) 0 47 (25.3) 2 (1.1)
COMBO450 Z encorafenib 450 mg QD þ binimetinib 45 mg BID; ENCO300 Z encorafenib 300 mg QD; VEM Z vemurafenib 960 mg BID.
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Fig. 5. Adverse events associated with BRAF inhibitors and MEK inhibitors.
Table 6
Select adverse events of interest occurring in the first 6 months, 6e12 months, 12e18 months and 18e24 months for patients on COMBO450 for
at least 24 months.
Category 0 - <6 months n (%) 6 to <12 months n (%) 12 to <18 months n (%) 18 to <24 months n (%)
Left ventricular dysfunction 3 (5.1) 2 (3.4) 2 (3.4) 1 (1.7)
Rash 9 (15.3) 6 (10.2) 3 (5.1) 2 (3.4)
Basal cell carcinoma 1 (1.7) 0 () 0 () 0 ()
Skin papilloma 3 (5.1) 3 (5.1) 0 () 2 (3.4)
Serous retinopathy 9 (15.3) 5 (8.5) 7 (11.9) 3 (5.1)
Photosensitivity 3 (5.1) 0 () 0 () 2 (3.4)
Pyrexia 8 (13.6) 4 (6.8) 4 (6.8) 1 (1.7)
Transaminases increased 6 (10.2) 1 (1.7) 1 (1.7) 0 ()
Cutaneous squamous cell carcinoma 1 (1.7) 0 () 1 (1.7) 1 (1.7)
Dermatitis acneiform 1 (1.7) 2 (3.4) 1 (1.7) 0 ()
Blood bilirubin increased 0 () 0 () 1 (1.7) 0 ()
The total number of patients on COMBO450 treatment for at least 24 months is 59, which is the denominator of each category. If a patient had the
same AE occur in multiple time ranges, the patient is counted in each of the time ranges. AE Z adverse event.
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